3 Undervalued Pharmaceuticals Stocks for Monday, November 18
Discover the top 3 undervalued Pharmaceuticals stocks for Monday, November 18 based on AAII’s Stock Grades.Aneeqa Nadeem
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer’s to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer’s disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Commentary & Analysis
Financial Summary
| Share Statistics | SPRC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4.1 | $579.1 | 3% |
|
| Shares Out (Mil) | 0.4 | 43.0 | 2% |
|
| Institutional Ownership | 13.3% | 84.3% | 8% |
|
| Float (Mil) | 0.6 | 46.8 | 1% |
|
| Beta | 2.48 | 0.62 | 96% |
|
| Avg Daily Volume (000s) | 900 | 285 | 69% |
|
| Price Change (52-week) |
(87.4%) | 63.8% | 5% |
|
| Growth | SPRC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (28.4%) | (1.4%) | 14% |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SPRC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $272 | 2% |
|
| Net Income (TTM) (Mil) | ($12) | ($11) | 28% |
|
| EPS (TTM) | ($98.071) | ($0.500) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($4) | ($6) | 25% |
|
| Net Cash Flow (TTM) (Mil) | $3 | $4 | 51% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($1) | $522 | 3% |
|
| Valuation | SPRC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.61 | 2.73 | 11% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | SPRC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 73.7% | 65.9% | 84% |
|
| Net Margin | na | 0.7% | na |
|
| ROA | (135.6%) | (24.6%) | 4% |
|
| ROE | (196.5%) | (19.7%) | 4% |
|
| Liabilities to Assets | 32.5% | 35.5% | 23% |
|
| F-Score | 1 | 3 | na |
|
SciSparc Ltd. did not pass any screens on 7/31/2026.
